Compare Organon & Co. Common Stock (OGN) vs Onto Innovation (ONTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Onto Innovation — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Onto Innovation trades at $234.87 (market cap $12.93B). The key difference: Onto Innovation is far larger — about 3.6× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Onto Innovation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Onto Innovation for 7 Days on average.
| OGN | ONTO | |
|---|---|---|
Market Cap | $3.62B | $12.93B |
Volume | 2,892,999 | 1,098,259 |
Sector | Health | Technology |
52-Week High | $13.81 | $378.45 |
52-Week Low | $5.70 | $124.09 |
Typical Hold Time | 0 Days | 7 Days |
Enterprise Value | $11.04B | $12.52B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
ONTO trades at $263.55, down 3.72% with bearish technical signals but strong analyst support. The stock shows mixed earnings performance with a Q2 2026 beat but misses in prior quarters. Revenue grew to $1.01B in 2025 with 11.84% net margin, though valuation remains elevated at P/E 98.71. Recent news highlights a $1.1B backlog and strategic partnerships in semiconductor manufacturing.
Outlook remains positive with 100% analyst buy ratings and $387 consensus target suggesting 47% upside. Key risks include high valuation multiples and semiconductor cycle volatility. Growth catalysts include AI-driven demand and Dragonfly G5 product momentum, though execution on backlog conversion is critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Onto Innovation
Onto Innovation provides process control solutions for semiconductor manufacturing. Its inspection and metrology systems help chipmakers measure, analyze, and detect defects on wafers and advanced packages.
Read more on ONTO →
